Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Connective and Soft Tissue » Neoplasms, Connective Tissue » Mastocytosis
Diseases [C] » Immune System Diseases [C20] » Mast Cell Activation Disorders » Mastocytosis
Description
A rare neoplastic disorder characterized by a clonal proliferation of MAST CELLS, associated with KIT-D816 mutations, and accompanied by aberrant mast cell activation. The abnormal increase of MAST CELLS may occur in only the skin (MASTOCYTOSIS, CUTANEOUS), in extracutaneous tissues involving multiple organs (MASTOCYTOSIS, SYSTEMIC), or in solid tumors (MASTOCYTOMA). MeSH
Hierarchy View
Subtype Terms (4)
Mastocytosis, Cutaneous
4 drugs (3 approved, 1 experimental)
Mastocytosis, Systemic
28 drugs (19 approved, 9 experimental)
Approved Indicated Drugs (3)
Phase 1 Indicated Drugs (2)
Other Experimental Indicated Drugs (1)
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (19)
Organization Involved with Phase 1 Indications (2)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.